학술논문
Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study.
Document Type
Article
Author
Hernández-Preciado, Martha Rocio; Marquez-Pedroza, Jazmin; Sánchez-Rosales, Nayeli Alejandra; García-Rivera, José de Jesús; Kobayashi-Gutiérrez, Antonio; Torres-Mendoza, Blanca Miriam; Chavarría-Avila, Efraín; Montaño-Serrano, Raúl Alejandro; Cortes-Enriquez, Fernando; Mireles-Ramírez, Mario Alberto
Source
Subject
*HEALTH services administration
*NATALIZUMAB
*RITUXIMAB
*MULTIPLE sclerosis
*FINGOLIMOD
*JOHN Cunningham virus
*
*
*
*
*
Language
ISSN
2077-0383
Abstract
The objective of this study was to evaluate the clinical files of patients with RRMS who started rituximab (RTX) compared with a second-line treatment (natalizumab (NTZ) or fingolimod (FTY)). This was a historical cohort study. We compared the effect according to the Expanded Disability Status Scale (EDSS) and the number of relapses in RRMS patients receiving these treatments after a mean period of 12 months. We found a statistically significant difference (p < 0.001) when comparing the EDSS scores and the annual relapse rates of patients receiving RTX with those receiving NTZ or FTY. This study is essential for our clinical practice, since patients with limited treatment options represent a challenge with regard to the management of their medical care. However, clinical trials and prospective studies with long follow-up periods are necessary to provide sufficient evidence on the efficacy of RTX and thus include this treatment in the therapeutic profile of patients with MS. [ABSTRACT FROM AUTHOR]